Le consortium ODIN a publié un document d'orientation dans Open Access Government intitulé « La surveillance environnementale comme sentinelle des épidémies émergentes : les enseignements tirés du mpox en Afrique ...
The ODIN Consortium has published a policy paper in Open Access Government titled “Environmental surveillance as a sentinel for emerging outbreaks: Lessons from mpox in Africa.” Drawing on experience from ...
The three-day intensive training on the “One Health Approach to Early Warning and Detection of Marburg Virus & Other Filoviruses in West Africa (Phase 2: Liberia Component)” was successfully held ...
Supa-at Asarath, Napat Khirikoekkong, Khin Maung Lwin, Phaik Yeong Cheah, and colleagues reflect on engagement with the Tak Province Community Ethics Advisory Board (T-CAB), established in 2009 on the Thai-Myanmar ...
The Learning to Harness Innovation in Global Health for Quality Care (HIGH-Q) programme was implemented in the newborn units in Kenyan county hospitals from January 2021 to September 2025. ...
On Sept 8, 2025, West African Ministers of Health pledged their joint commitment to advance development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant regional health security threat posed by the disease Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
Developed from a systematic review of peer-reviewed studies, this platform allows users to explore findings by country, vaccine, drug, disease, surveillance method, participant group, and study year. The tool supports vaccine and drug developers, pharmacovigilance programs, and public health stakeholders ... Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
SPEAC’s Special Populations team, in collaboration with Instituto de Efectividad Clínica y Sanitaria (IECS) and Tulane University, has launched an LSR and meta-analysis tool focused on the safety, effectiveness, and immunogenicity of mpox vaccines Read more
CEPI is pleased to announce that two leading scientific organizations, the International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA), have officially joined the CLN. The network now comprises 20 facilities... Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
